{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:59:35Z","timestamp":1791478775767,"version":"4.3.4"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100017950","name":"the Shanghai Municipal Health Commission Clinical Research Youth Project","doi-asserted-by":"publisher","award":["20224Y0121"],"award-info":[{"award-number":["20224Y0121"]}],"id":[{"id":"10.13039\/100017950","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the National Natural Science Foundation-Youth Foundation","award":["82204544"],"award-info":[{"award-number":["82204544"]}]},{"name":"the Fudan Undergraduate Research Opportunities Program","award":["22075"],"award-info":[{"award-number":["22075"]}]},{"name":"the National Undergraduate Training Program on Innovation and Entrepreneurship","award":["202310246074"],"award-info":[{"award-number":["202310246074"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Linezolid is a commonly prescribed antibiotic for multidrug-resistant enterococcal infections in liver transplant recipients (LTRs). However, changes in pharmacokinetics due to fluctuations in liver and renal functions, combined with the increased risk of thrombocytopenia, complicate its clinical use. This study aimed to characterize the exposure-thrombocytopenia risk relationship of linezolid in LTRs, and to identify safe dosing thresholds to promote rational drug use.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A retrospective analysis was conducted on adult LTRs treated with linezolid at Zhongshan Hospital between January 2019 and May 2022. A population exposure-safety model was developed and used to establish a thrombocytopenia risk threshold and optimize initial dosing strategies through Monte Carlo simulations. An area under the concentration\u2013time curve (AUC) calculator was developed to facilitate individualized dose adjustments.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Exposure-safety analysis revealed that an AUCss,24h threshold of 291.7\u2005mg\/L\u00b7h was associated with an increased risk of thrombocytopenia. Monte Carlo simulations showed that current covariate-based initial dosing recommendations were suboptimal, highlighting the necessity of therapeutic drug monitoring (TDM) to improve outcomes in LTRs. The online AUC calculator developed in this study offers a practical tool for clinicians to implement timely dose adjustments (https:\/\/optimaldose.shinyapps.io\/LinezolidAUC\/).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This study provides the first comprehensive analysis of linezolid exposure and its relationship to thrombocytopenia risk in LTRs. The findings underscore the importance of AUC-guided dosing and TDM in optimizing treatment outcomes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkaf147","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T14:57:30Z","timestamp":1747148250000},"page":"1915-1925","source":"Crossref","is-referenced-by-count":3,"title":["Population pharmacokinetics and thrombocytopenia risk assessment of linezolid in liver transplant recipients"],"prefix":"10.1093","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3272-5554","authenticated-orcid":false,"given":"Xiaoping","family":"Shi","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Zhongshan Hospital, Fudan University , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyu","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanyu","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghui","family":"Lao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Zhongshan Hospital, Fudan University , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Zhongshan Hospital, Fudan University , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Zhongshan Hospital, Fudan University , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianzhou","family":"Lv","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Zhongshan Hospital, Fudan University , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingfeng","family":"He","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqiang","family":"Xiang","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, Zhongshan Hospital, Fudan University , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3295-619X","authenticated-orcid":false,"given":"Xiao","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,13]]},"reference":[{"key":"2025070104562391000_dkaf147-B1","doi-asserted-by":"publisher","first-page":"e13549","DOI":"10.1111\/ctr.13549","article-title":"Vancomycin-resistant Enterococcus in solid organ transplant recipients: guidelines from the American society of transplantation infectious diseases community of practice","volume":"33","author":"Nellore","year":"2019","journal-title":"Clin Transplant"},{"key":"2025070104562391000_dkaf147-B2","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/jac\/dkn442","article-title":"Biliary penetration and pharmacodynamic exposure of linezolid in liver transplant patients","volume":"63","author":"Pea","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"2025070104562391000_dkaf147-B3","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/j.1399-3062.2011.00617.x","article-title":"Efficacy and safety of linezolid in liver transplant patients","volume":"13","author":"Radunz","year":"2011","journal-title":"Transpl Infect Dis"},{"key":"2025070104562391000_dkaf147-B4","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.transproceed.2012.01.065","article-title":"Recipient and perioperative risk factors associated with liver transplant graft outcomes","volume":"44","author":"Sirivatanauksorn","year":"2012","journal-title":"Transplant Proc"},{"key":"2025070104562391000_dkaf147-B5","doi-asserted-by":"publisher","first-page":"372","DOI":"10.3390\/jcm8030372","article-title":"Incidence and impact of acute kidney injury after liver transplantation: a meta-analysis","volume":"8","author":"Thongprayoon","year":"2019","journal-title":"J Clin Med"},{"key":"2025070104562391000_dkaf147-B6","author":"Pfizer Inc"},{"key":"2025070104562391000_dkaf147-B7","doi-asserted-by":"publisher","first-page":"e00605-19","DOI":"10.1128\/AAC.00605-19","article-title":"Reappraisal of linezolid dosing in renal impairment to improve safety","volume":"63","author":"Crass","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2025070104562391000_dkaf147-B8","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.ijantimicag.2017.06.023","article-title":"Linezolid in liver failure: exploring the value of the maximal liver function capacity (LiMAx) test in a pharmacokinetic pilot study","volume":"50","author":"Wicha","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"2025070104562391000_dkaf147-B9","doi-asserted-by":"publisher","first-page":"e00133-20","DOI":"10.1128\/AAC.00133-20","article-title":"Population pharmacokinetics and dosage optimization of linezolid in patients with liver dysfunction","volume":"64","author":"Zhang","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2025070104562391000_dkaf147-B10","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1111\/bcp.15368","article-title":"Parametric population pharmacokinetics of linezolid: a systematic review","volume":"88","author":"Qin","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"2025070104562391000_dkaf147-B11","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1007\/s00228-023-03542-z","article-title":"Risk factors for thrombocytopenia in patients receiving linezolid therapy: a systematic review and meta-analysis","volume":"79","author":"Zhang","year":"2023","journal-title":"Eur J Clin Pharmacol"},{"key":"2025070104562391000_dkaf147-B12","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1089\/sur.2013.190","article-title":"Thrombocytopenia associated with linezolid therapy in solid organ transplant recipients: a retrospective cohort study","volume":"16","author":"Tessier","year":"2015","journal-title":"Surg Infect (Larchmt)"},{"key":"2025070104562391000_dkaf147-B13","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.3748\/wjg.v24.i13.1386","article-title":"Thrombocytopenia after liver transplantation: should we care?","volume":"24","author":"Takahashi","year":"2018","journal-title":"World J Gastroenterol"},{"key":"2025070104562391000_dkaf147-B14","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s00228-023-03511-6","article-title":"External validation of population pharmacokinetic models of vancomycin in postoperative neurosurgical patients","volume":"79","author":"Wei","year":"2023","journal-title":"Eur J Clin Pharmacol"},{"key":"2025070104562391000_dkaf147-B15","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s00280-022-04465-9","article-title":"Population pharmacokinetics of cisplatin in small cell lung cancer patients guided with informative priors","volume":"90","author":"Aguiar Zdovc","year":"2022","journal-title":"Cancer Chemother Pharmacol"},{"key":"2025070104562391000_dkaf147-B16","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40779-020-00244-w","article-title":"Expert consensus on the diagnosis and treatment of thrombocytopenia in adult critical care patients in China","volume":"7","author":"Song","year":"2020","journal-title":"Mil Med Res"},{"key":"2025070104562391000_dkaf147-B17","author":"National Health Committee of the People's Republic of China"},{"issue":"Suppl 2","key":"2025070104562391000_dkaf147-B18","doi-asserted-by":"publisher","first-page":"ii17","DOI":"10.1093\/jac\/dkg248","article-title":"Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with gram-positive infections","volume":"51","author":"MacGowan","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"2025070104562391000_dkaf147-B19","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.2165\/00003088-200342150-00007","article-title":"Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme","volume":"42","author":"Rayner","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"2025070104562391000_dkaf147-B20","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1093\/jac\/dks153","article-title":"Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients","volume":"67","author":"Pea","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"2025070104562391000_dkaf147-B21","doi-asserted-by":"publisher","first-page":"732503","DOI":"10.3389\/fphar.2021.732503","article-title":"Model based identification of linezolid exposure-toxicity thresholds in hospitalized patients","volume":"12","author":"Fang","year":"2021","journal-title":"Front Pharmacol"},{"key":"2025070104562391000_dkaf147-B22","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1&lt;32::AID-CNCR2820030106&gt;3.0.CO;2-3","article-title":"Index for rating diagnostic tests","volume":"3","author":"Youden","year":"1950","journal-title":"Cancer"},{"key":"2025070104562391000_dkaf147-B23","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.ijantimicag.2014.05.010","article-title":"Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients","volume":"44","author":"Matsumoto","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"2025070104562391000_dkaf147-B24","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1128\/AAC.01185-10","article-title":"Population pharmacokinetic and pharmacodynamic analysis of linezolid and a hematologic side effect, thrombocytopenia, in Japanese patients","volume":"55","author":"Sasaki","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2025070104562391000_dkaf147-B25","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s40262-016-0463-7","article-title":"Clinical determinants of target non-attainment of linezolid in plasma and interstitial space fluid: a pooled population pharmacokinetic analysis with focus on critically ill patients","volume":"56","author":"Minichmayr","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"2025070104562391000_dkaf147-B26","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1111\/bcp.13262","article-title":"Population pharmacokinetics and pharmacodynamics of linezolid-induced thrombocytopenia in hospitalized patients","volume":"83","author":"Tsuji","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"2025070104562391000_dkaf147-B27","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1128\/AAC.47.2.548-553.2003","article-title":"Population pharmacokinetics of linezolid in patients treated in a compassionate-use program","volume":"47","author":"Meagher","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"2025070104562391000_dkaf147-B28","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1177\/0091270009337947","article-title":"Population pharmacokinetic analysis of linezolid in patients with infectious disease: application to lower body weight and elderly patients","volume":"49","author":"Abe","year":"2009","journal-title":"J Clin Pharmacol"},{"key":"2025070104562391000_dkaf147-B29","doi-asserted-by":"publisher","first-page":"5254","DOI":"10.1128\/AAC.00356-16","article-title":"Predictors of inadequate linezolid concentrations after standard dosing in critically ill patients","volume":"60","author":"Taubert","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2025070104562391000_dkaf147-B30","doi-asserted-by":"publisher","first-page":"106572","DOI":"10.1016\/j.ijantimicag.2022.106572","article-title":"Population pharmacokinetics and toxicodynamics of continuously infused linezolid in critically ill patients","volume":"59","author":"Wicha","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"2025070104562391000_dkaf147-B31","doi-asserted-by":"publisher","first-page":"1310309","DOI":"10.3389\/fphar.2024.1310309","article-title":"Towards a better detection of patients at-risk of linezolid toxicity in clinical practice: a prospective study in three Belgian hospital centers","volume":"15","author":"Thirot","year":"2024","journal-title":"Front Pharmacol"},{"key":"2025070104562391000_dkaf147-B32","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.12659\/MSM.915128","article-title":"Efficacy and safety of steroid therapy for posttransplant hyperbilirubinemia caused by early allograft dysfunction: a randomized controlled trial","volume":"25","author":"Yang","year":"2019","journal-title":"Med Sci Monit"},{"key":"2025070104562391000_dkaf147-B33","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1080\/17512433.2023.2181160","article-title":"Hematological toxicities associated with linezolid therapy in adults: key findings and clinical considerations","volume":"16","author":"Cattaneo","year":"2023","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2025070104562391000_dkaf147-B34","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3109\/00365548.2011.608712","article-title":"Correlation between serum linezolid concentration and the development of thrombocytopenia","volume":"44","author":"Hiraki","year":"2012","journal-title":"Scand J Infect Dis"},{"key":"2025070104562391000_dkaf147-B35","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.ijantimicag.2013.02.020","article-title":"Linezolid plasma concentrations and occurrence of drug-related haematological toxicity in patients with gram-positive infections","volume":"41","author":"Cattaneo","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"2025070104562391000_dkaf147-B36","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1097\/TP.0000000000003865","article-title":"Prognostic impact of early recovering acute kidney injury following liver transplantation: a multicenter retrospective study","volume":"106","author":"Dewitte","year":"2022","journal-title":"Transplantation"},{"key":"2025070104562391000_dkaf147-B37","doi-asserted-by":"publisher","first-page":"996","DOI":"10.3390\/antibiotics11080996","article-title":"Population pharmacokinetic and pharmacodynamic analysis of dalbavancin for long-term treatment of subacute and\/or chronic infectious diseases: the major role of therapeutic drug monitoring","volume":"11","author":"Cojutti P","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"2025070104562391000_dkaf147-B38","doi-asserted-by":"publisher","first-page":"1364681","DOI":"10.3389\/fphar.2024.1364681","article-title":"Vancomycin population pharmacokinetics and dosing proposal for the initial treatment in obese adult patients","volume":"15","author":"Polaskova","year":"2024","journal-title":"Front Pharmacol"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/7\/1915\/63167029\/dkaf147.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/7\/1915\/63167029\/dkaf147.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T08:56:28Z","timestamp":1751360188000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/7\/1915\/8129611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,13]]},"references-count":38,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,5,13]]},"published-print":{"date-parts":[[2025,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf147","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,5,13]]}}}